Star weight loss therapy megalrutide producer novo, on May 14, local time in the European obesity conference showed a company so far the longest clinical follow-up data, the results show that with heart disease but no diabetes overweight and obese patients, in continuous megallutide weight loss drug Wegovy treatment after four years, can still can maintain the average weight loss of 10%.

 Martin Holst Lange, head of drug development at Novo Nordisk, said: " We found that once patients start to lose weight significantly, they are not likely to lose weight if they continue using the drug."Novo Nordisk had previously warned that patients could cause weight regain if they stopped taking. But there have been doubts about the long-term effectiveness of the drug.

 This large-scale clinical study, Select, enrolled more than 17,600 patients, with a average weight loss of about 10% after 65 weeks of Wegovy and a 10% weight loss after four years of medication.

 Select Clinical trials also showed that no other side effects of taking such weight-loss drugs were found within four years. Previously, the well-known side effects are mainly gastrointestinal side effects, such as nausea, diarrhea, vomiting, and constipation.

 Last year, the results of a clinical trial of people with cardiovascular disease showed that Wegovy could reduce the risk of heart attack, stroke or heart-related death by 20 percent in people at cardiovascular risk, obesity or overweight. Experts say the results also raise new research questions about whether people who are not obese or overweight but have had heart disease or stroke can benefit from drugs such as Wegovy.

 The long-term effect of weight loss drugs is one of the key points of the next stage of pharmaceutical giants. Amgen recently released a weight loss therapy, MariTide, which takes it less frequently than Novo Nordisk's Wegovy and Lilly's Zepbound, and may provide longer weight loss. MariTide Injection once a month, which is more convenient than the current weekly injection on the market, and can also reduce the supply pressure.

 Novo Nordisk said this month that more than 25,000 new Wegovy users exist in the US each week. Six percent of respondents in the US said they are currently using the GLP-1 drug, meaning the number of people using the drug is 15 million. Novo Nordisk said at an investor meeting in March that Wegovy, the simegallutide drug for weight loss, is expected to be approved on the Chinese mainland this year, but will be limited in the early stage of the launch, focusing on self-funded patients.

 In addition, Novo Nordisk submitted an application for a clinical trial of class 1 new oral weight loss agent Amycretin tablets in China last month. Amycretin Targeting amylin, which in the pancreas affects starvation, and similar to GLP-1, amylin also slows gastric emptying and promotes satiety.

A small phase 1 clinical study released by the company showed that after 12 weeks of treatment with the drug, patients had an average weight loss of 13.1 percent, more than the 6% weight loss of older simegallutide in the same cycle. The interim trial of the drug will begin in the second half of this year, with results expected in early 2026.